Bioinformatics Market to Reach $43.5 Billion by 2030, Driven by AI Integration and Expanding Genomics Applications

“According to BCC Research, the global bioinformatics market is projected to grow from $23.5 billion in 2025 to $43.5 billion by 2030, at a CAGR of 13.1%, driven by exponential growth in biological and genomic data, expanding precision medicine and the integration of AI-powered analytics across life sciences research and drug discovery.”

Boston, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The global bioinformatics market is projected to grow from $20.9 billion in 2024 to $43.5 billion by 2030, advancing at a compound annual growth rate (CAGR) of 13.1% during the 2025–2030 forecast period. This analysis is detailed in Bioinformatics: Technologies and Global Markets, a newly published report by BCC Research examining the computational tools, software platforms, and services reshaping biological research and drug development worldwide.

Key Findings

• Market Scale and Momentum: The bioinformatics market is on track to more than double in value over six years, underpinned by surging demand across genomics, proteomics, and data-intensive biological research disciplines. The convergence of next-generation sequencing (NGS), multi-omics platforms, and AI-driven analytics is accelerating investment in computational biology infrastructure at a pace that outstrips broader life sciences sector growth.

• North America Leads Global Adoption: North America commands 47.7% of the global bioinformatics market, reflecting deep institutional investment in genomic research, a mature biopharma ecosystem, and robust venture capital activity in digital biology. The region's dominance is further reinforced by proximity to leading technology vendors and a concentration of top-tier academic research centers.

• AI and Cloud Computing Redefine the Toolkit: The integration of artificial intelligence, machine learning, and cloud-based deployment into bioinformatics workflows is fundamentally restructuring the competitive landscape. AI-driven modeling now enables ADMET profile predictions that compress preclinical timelines, while pay-as-you-go cloud services are democratizing access to high-performance computing resources across geographies and institution sizes.

• Personalized Medicine and Oncology as Structural Growth Engines: Increasing demand for personalized medicine and targeted cancer therapies is a defining demand-side driver. Growing oncology research funding is accelerating bioinformatics adoption specifically for tumor genomics, biomarker identification, and treatment stratification — areas where computational analysis has moved from supplementary to mission-critical.

• Emerging Technologies Expanding the Frontier: Long-read sequencing platforms such as PacBio HiFi, single-cell multiomics, quantitative high-throughput screening combined with machine learning, and national bio data platforms — including South Korea's initiative targeting millions of genomic data cases by 2035 — represent the next wave of bioinformatics capability. Digital twin technology and AI-powered software, as evidenced by Siemens' acquisition of Dotmatics, signal increasing convergence between industrial informatics and life sciences.

• Competitive Landscape: Key participants shaping the global bioinformatics market include Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Dassault Systèmes, Bio-Rad Laboratories Inc., Siemens Healthineers AG, PacBio, Revvity, DNASTAR, Qlucore AB, Molecular Networks GmbH, MacVector Inc., Real Time Genomics, and Excelra.

Market Drivers

The bioinformatics market is being propelled by the exponential growth of data generated through high-throughput sequencing, imaging, and multi-omics studies, creating urgent demand for scalable storage systems, advanced analytical platforms, and specialized talent. Public funding mechanisms — including France 2030, Horizon Europe, and UKRI programs — are providing critical infrastructure support, while public-private collaborations such as the BD Biosciences and CSIR-IGIB single-cell multiomics Centre of Excellence in India are extending capacity into emerging economies. The uptake of NGS technologies and cloud services in markets such as China further broadens the global addressable opportunity.

Cheminformatics is emerging as a particularly dynamic sub-segment, with AI-driven modeling enabling drug discovery teams to predict toxicity profiles and prioritize candidates with greater precision and speed. Open-source tools including RDKit and Bioclipse are simultaneously lowering the barrier to entry for academic and smaller commercial institutions, widening adoption across the research ecosystem.

Investment Considerations

Investors evaluating bioinformatics exposure should consider that the sector sits at the intersection of two durable megatrends: the digitization of biology and the industrialization of drug discovery. The highest-conviction opportunities lie with platform companies capable of integrating multi-omics data at scale — particularly those embedded in oncology workflows and personalized medicine pipelines where switching costs are high and regulatory tailwinds are favorable. Key risks include the substantial cost of advanced software licensing, a constrained and expensive bioinformatics talent pool — with U.S. and European salaries ranging from $90,000 to over $110,000 annually as of 2026 — and regulatory complexity around genomic data privacy across jurisdictions including China's PIPL, India's DPDP Act, and Japan's APPI. Companies with diversified geographic exposure and cloud-native architectures are best positioned to navigate this fragmented compliance environment. Uneven regional adoption, particularly across Latin America, presents a longer-dated but meaningful expansion opportunity.

About the Report

Bioinformatics: Technologies and Global Markets provides comprehensive market sizing, segmentation by technology and application, competitive intelligence, and a forecast spanning 2025–2030 across global and regional dimensions.

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

BCC Research LLC
50 Milk St., Ste. 16, Boston, MA 02109
press@bccresearch.com  |  +1 781-489-7301
www.bccresearch.com